Clinical Trial Update: Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating erdafitinib combined with abiraterone acetate or enzalutamide in double negative prostate cancer; study terminated with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Carcinoma
• Double-negative Prostate Carcinoma
• Prostate Adenocarcinoma
• Prostate Cancer Ajcc V8
• Prostate Carcinoma
• Stage Iva Prostate Cancer Ajcc V8
• Stage Ivb Prostate Cancer Ajcc V8

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Enzalutamide (enzalutamide)
• Erdafitinib (erdafitinib)

Snippet

Sponsor: University of Washington | Conditions: Castration-Resistant Prostate Carcinoma, Double-Negative Prostate Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2023-09-28